Jonathan Finn

Chief Scientific Officer

Tome Biosciences

United States

Research Interests

Explore related searches

Professors in United States Professors in Tissue Engineering Tissue Engineering professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jonathan Finn is the Chief Scientific Officer at Tome Biosciences in the United States. His research focuses on immunotherapy, particularly the engineering of iPSC-derived immune cells and exosome-based therapeutics. He has contributed to various studies on extracellular vesicle function and gene therapy, emphasizing the impact of intensive immunosuppression on transgene antibodies. Dr. Finn's work aims to advance therapeutic approaches through innovative platforms and insights into immune system engineering.

Articles (6)

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Benjamin J. Samelson‐Jones

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonathan Finn

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy

Transfection reagent artefact likely accounts for some reports of extracellular vesicle function

Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants

A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Exosome-based therapeutics: ready for prime time

Collaborators (1)

Benjamin J. Samelson‐Jones

Make your next move.